NORWALK, Conn., Jan. 15, 2015 /PRNewswire/ -- UBM Medica US announces that Endocrinology Network, a leading online community for endocrinologists and other clinicians who treat patients with T2DM offers comprehensive and up-to-date coverage of the sodium glucose cotransporter 2 (SGLT2) inhibitors.
The most recent studies of this newest class of oral antidiabetes drugs find that in addition to glucose lowering effects, empagliflozin, dapagliflozin, and canagliflozin also promote weight loss and reduce blood pressure in patients with type 2 diabetes. A nephroprotective effect has been seen as well. The unique mechanism of action of these drugs and the emerging understanding of their pleiotropic effects will require regular updates in clinical education.
Some highlights of SGLT2 inhibitor coverage include:
- Empagliflozin Lowered BP in Patients with T2DM and Hypertension: An adjusted mean difference in 24-hour blood pressure was seen for measures of both systolic (-3.44 mm Hg) and diastolic (-1.5 mm Hg) blood pressure compared with placebo.
- SGLT2 Inhibitor Lowers Blood Pressure Across Medication Classes: In SGLT2 inhibitor-treated patients with type 2 diabetes who also had treated hypertension, the drop in blood pressure observed was similar for a diuretic, a beta blocker, and a calcium channel blocker.
- SGLT2 Inhibitor Reduces Visceral Adiposity in T2DM: A new study suggests that empagliflozin may help reduce measures of visceral adiposity through a redistribution of fat to less vulnerable body areas.
- SGLT2 Inhibitors: What Role in Nephroprotection? Preliminary evidence suggests that this novel class of drugs may suppress glomerular hyperfiltration, hypoglycemia-related tubular growth, kidney hypertrophy, and other harbingers of diabetic nephropathy.
About UBM Medica US
Addressing today's healthcare information needs, UBM Medica US, delivers strategic, integrated communications solutions and comprehensive reach -- online, in print, via custom programs and live events. Improving the effectiveness of healthcare through information and education, UBM Medica US provides unbiased clinical, practical, and business information for physicians, providers and payers resulting in improved quality of care for patients around the world. Through journals, magazines, online communities, live and digital events, and other valuable resources, UBM Medica US also delivers comprehensive communication solutions for the pharmaceutical and related industries. Online communities include CancerNetwork.com, ConsultantLive.com, DiagnosticImaging.com, RheumatologyNetwork.com, OBGYN.net, PhysiciansPractice.com, PsychiatricTimes.com and SearchMedica.com. UBM Medica US is part of UBM Connect which, through a range of aligned interactive environments, both physical and digital – increases business effectiveness for both customers and audiences through meaningful experiences, knowledge and connections. Headquartered in New York, UBM Connect brings together UBM's healthcare business, UBM Medica US; UBM Canon's advanced design and manufacturing event, online and print brands; UBM Connect New York's catering, cruise shipping, customer management, and fine, specialty and custom chemical communities; and UBM Mexico's concrete show. For more information, visit www.UBMMedicaUS.com.
About UBM plc
UBM plc is a global events-led marketing services and communications company. We help businesses do business, bringing the world's buyers and sellers together at events and online, as well as producing and distributing news and specialist content. Our 5,500 staff in more than 30 countries are organized into expert teams which serve commercial and professional communities, helping them to do business and their markets to work effectively and efficiently.
For more information, go to www.ubm.com; follow us on Twitter at @UBM_plc to get the latest UBM corporate news.
Jason J. Golden
Content Marketing Manager
SOURCE UBM Medica US